Biotricity (BTCY) Competitors $0.28 -0.01 (-4.08%) (As of 12/20/2024 04:34 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends BTCY vs. FEMY, CODX, DRIO, VVOS, ALUR, NRXS, MBOT, NEPH, LUCY, and LFWDShould you be buying Biotricity stock or one of its competitors? The main competitors of Biotricity include Femasys (FEMY), Co-Diagnostics (CODX), DarioHealth (DRIO), Vivos Therapeutics (VVOS), Allurion Technologies (ALUR), NeurAxis (NRXS), Microbot Medical (MBOT), Nephros (NEPH), Innovative Eyewear (LUCY), and ReWalk Robotics (LFWD). These companies are all part of the "medical equipment" industry. Biotricity vs. Femasys Co-Diagnostics DarioHealth Vivos Therapeutics Allurion Technologies NeurAxis Microbot Medical Nephros Innovative Eyewear ReWalk Robotics Femasys (NASDAQ:FEMY) and Biotricity (NASDAQ:BTCY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation, community ranking and risk. Which has better valuation and earnings, FEMY or BTCY? Biotricity has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFemasys$1.26M19.80-$14.25M-$0.81-1.35Biotricity$12.06M0.57-$14.09M-$1.37-0.20 Does the media prefer FEMY or BTCY? In the previous week, Femasys' average media sentiment score of 0.00 equaled Biotricity'saverage media sentiment score. Company Overall Sentiment Femasys Neutral Biotricity Neutral Is FEMY or BTCY more profitable? Biotricity has a net margin of -97.05% compared to Femasys' net margin of -1,435.77%. Biotricity's return on equity of 0.00% beat Femasys' return on equity.Company Net Margins Return on Equity Return on Assets Femasys-1,435.77% -141.49% -82.30% Biotricity -97.05%N/A -221.26% Does the MarketBeat Community believe in FEMY or BTCY? Femasys received 31 more outperform votes than Biotricity when rated by MarketBeat users. Likewise, 72.09% of users gave Femasys an outperform vote while only 0.00% of users gave Biotricity an outperform vote. CompanyUnderperformOutperformFemasysOutperform Votes3172.09% Underperform Votes1227.91% BiotricityOutperform VotesNo VotesUnderperform Votes2100.00% Do institutionals and insiders hold more shares of FEMY or BTCY? 65.3% of Femasys shares are owned by institutional investors. Comparatively, 3.9% of Biotricity shares are owned by institutional investors. 12.3% of Femasys shares are owned by company insiders. Comparatively, 10.1% of Biotricity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, FEMY or BTCY? Femasys has a beta of -2.89, suggesting that its stock price is 389% less volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Do analysts rate FEMY or BTCY? Femasys currently has a consensus target price of $10.00, indicating a potential upside of 817.43%. Given Femasys' stronger consensus rating and higher possible upside, analysts plainly believe Femasys is more favorable than Biotricity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Biotricity 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryFemasys beats Biotricity on 10 of the 16 factors compared between the two stocks. Ad Porter & CompanyVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Get Biotricity News Delivered to You Automatically Sign up to receive the latest news and ratings for BTCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTCY vs. The Competition Export to ExcelMetricBiotricitySurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.17M$4.34B$5.14B$9.08BDividend YieldN/A44.57%5.09%4.23%P/E Ratio-0.2025.3790.1317.20Price / Sales0.5745.901,117.09117.04Price / CashN/A43.4443.1037.85Price / Book-0.087.094.784.78Net Income-$14.09M$13.64M$120.31M$225.60M7 Day Performance-11.42%-2.93%-1.92%-1.23%1 Month Performance-11.11%-1.42%13.65%0.46%1 Year Performance-74.55%39.20%28.34%15.24% Biotricity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTCYBiotricityN/A$0.28-4.1%N/A-74.1%$7.17M$12.06M-0.2040High Trading VolumeFEMYFemasys2.1378 of 5 stars$1.15-3.4%$10.00+769.6%+22.6%$26.33M$1.26M-1.4730CODXCo-Diagnostics3.8295 of 5 stars$0.79-5.0%$1.50+89.8%-39.7%$25.23M$7.32M-0.60100DRIODarioHealth2.2551 of 5 stars$0.70-4.1%$4.00+468.2%-51.2%$24.00M$23.05M-0.75200News CoveragePositive NewsVVOSVivos Therapeutics2.8401 of 5 stars$4.95+7.4%$6.30+27.3%-57.7%$23.96M$13.80M-0.81160Positive NewsGap UpALURAllurion Technologies2.0375 of 5 stars$0.34-2.9%$2.88+755.7%-90.2%$21.63M$34.75M-0.70501Gap UpNRXSNeurAxisN/A$2.44-1.6%N/A+5.3%$17.03M$2.46M-1.3519Gap DownHigh Trading VolumeMBOTMicrobot Medical1.9092 of 5 stars$1.00flat$7.00+600.0%-29.2%$16.93MN/A-1.2520NEPHNephros1.6901 of 5 stars$1.55flat$5.00+222.6%-47.6%$16.34M$13.55M-17.2230Positive NewsLUCYInnovative Eyewear1.7076 of 5 stars$6.52+6.7%$20.00+206.7%-32.6%$15.92M$1.56M-0.669LFWDReWalk Robotics3.3589 of 5 stars$1.63-1.2%$13.00+697.5%N/A$14.36M$25.00M-0.6260Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Femasys Alternatives Co-Diagnostics Alternatives DarioHealth Alternatives Vivos Therapeutics Alternatives Allurion Technologies Alternatives NeurAxis Alternatives Microbot Medical Alternatives Nephros Alternatives Innovative Eyewear Alternatives ReWalk Robotics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BTCY) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biotricity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biotricity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
